The Comparison of two approach of drug transition in shoulder impingement patients

The Comparative Effect of Phonophoresis and Injection of Triamcinolone with lidocain on Pain, Disability, Quality of Life and Effectiveness of Treatments in Shoulder Impingement Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161221031506N3

Enrollment

Registered

2019-02-27

Start date

2018-12-06

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder Impingement Syndrome. Impingement syndrome of shoulder

Interventions

Intervention 1: Intervention group#1 (Injection): The triamcinolone (Cortiran, Iran hormone, Tehran, Iran) and lidocaine (Caspian, Iran tamin, Tehran, Iran) will be injected by the orthopedic physicia

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Pain less than 3 month Pain in the upper, outer arm especially when lifting of arm Aged 18-65 years Signs of shoulder impingement syndrome : Presence of at least two of the following 1) Painful arch movement during flexion or abduction of the shoulder 2) Positive Neer or Hawkins-Kennedy test 3) Painful resisted external rotation, abduction or painful jobe (empty can) test

Exclusion criteria

Exclusion criteria: Existence of type 3 acromion Existence of frozen shoulder ( the loss in passive shoulder range of motion greater than 50% as compared to the uninvolved side in at least 2 shoulder movements) Existence of neck radiculopathy Existence of Complete rupture of rotator cuff muscles (MRI findings) Existence of shoulder joint instability (Positive tests of sulcus or apprehension) Use of corticosteroid drugs in last 3 months History of RSD History of any neurological diseases History of rheumatoid diseases and shoulder osteoarthritis History of fracture or dislocation or surgery in the shoulder complex

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: visual analog scale.;Disability. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: by SPADI questionnaire.;Quality of life. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: by WORC questionnaire.;Treatment effect. Timepoint: discharge time. Method of measurement: by Global Rating Scale.	—

Measure

Time frame

Pain. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: visual analog scale.;Disability. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: by SPADI questionnaire.;Quality of life. Timepoint: visit time- after 10 days placebo intervention- after 10 days treatment period. Method of measurement: by WORC questionnaire.;Treatment effect. Timepoint: discharge time. Method of measurement: by Global Rating Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Mazaheri Tehrani

Mashhad University of Medical Sciences

mtmazaheri@outlook.com+98 51 3869 8719

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026